AHA GUIDELINES Bundle (free trial)

Atrial Fibrillation 2023 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/387790

Contents of this Issue


Page 131 of 131

Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. Source Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt L, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, omas KL, Times SS, Tisdale JE, Valente AM, Van Wagoner DR. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiolog y/American Heart Association Joint Committee on Clinical Practice Guidelines. [published online ahead of print Nov 30, 2023]. J Am Coll Cardiol. doi: 10.1016/j.jacc.2023.08.017 Copublished in Circulation. doi: 10.1161/CIR.0000000000001193. ACCAFIB10233 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2023 All rights reserved GuidelineCentral.com Abbreviations ACE, angiotensin-converting enzyme; ACHD, adult congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; AHRE, atrial high-rate episodes; ANS, autonomic nervous system; AP, accessory pathway; APT, antiplatelet therapy; ARB, angiotensin receptor blocker; AT, atrial tachycardia; AVNA, atrioventricular nodal ablation; BiVP, biventricular pacing ; BMI, body mass index; BP, blood pressure; bpm, beats per minute; BTK, Bruton's tyrosine kinase; CABG, coronary artery bypass gra surgery; CAD, coronary artery disease; CCD, chronic coronary disease; CHADS 2 , congestive heart failure, hypertension, age 75 years, diabetes mellitus, stroke/transient ischemia attack/ thromboembolism; CHA 2 DS 2 -VASc, congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years, sex category; CHD, congenital heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation; CrCl, creatinine clearance; CRT, cardiac resynchronization therapy; CTI, cavotricuspid isthmus; CVD, cardiovascular disease; DAT, dual antithrombotic therapy; DOAC, direct oral anticoagulant; ECG, electrocardiogram; EF, ejection fraction; eGFR, estimated glomerular filtration rate; FDA, US Food and Drug Administration; GDMT, guideline-directed management and therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; ICD, implantable cardioverter-defibrillator; ICH, intracranial hemorrhage; LA, le atrium; LAA, le atrial appendage; LAAO, le atrial appendage occlusion; LOE, Level of Evidence; LRFM, lifestyle risk factor modification; LV, le ventricular; LVEF, le ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OAC, oral anticoagulant; PAC, premature atrial contraction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PCC, prothrombin complex concentrate; PE, pulmonary embolism; PH, pulmonary hypertension; PHPVD, pulmonary hypertension with pulmonary vascular disease; PITP, pill-in-the-pocket; pLAAO, percutaneous le atrial appendage occlusion; PV, pulmonary veins; PVI, pulmonary vein isolation; QOL, quality of life; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trial; RV, right ventricular; RVP, right ventricular pacing ; SDB, sleep-disordered breathing ; SDOH, social determinants of health; SDM, shared decision-making ; S-LAAO, surgical removal of the le atrial appendage occlusion; SVT, supraventricular tachycardia; TEE, transesophageal echocardiogram; TIA, transient ischemic attack; UREG, underrepresented racial and ethnic groups; VF, ventricular fibrillation; VHD, valvular heart disease; VKA, vitamin K antagonist; VT, ventricular tachycardia; WPW, Wolff-Parkinson-White

Articles in this issue

Links on this page

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Atrial Fibrillation 2023 Update